Skip to main content
. 2022 Nov 23;12:1030798. doi: 10.3389/fonc.2022.1030798

Figure 2.

Figure 2

PFS (A) and OS (B) of patients in NSCLC treated with Apatinib. The mPFS and mOS were 4.4 months and 17.2 months in NSCLC treated with Apatinib, respectively.